Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
18.47
-0.07 (-0.38%)
At close: Mar 18, 2026, 4:00 PM EDT
18.00
-0.47 (-2.54%)
After-hours: Mar 18, 2026, 5:27 PM EDT

Caris Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2023
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
812.03412.26306.13258.49
Revenue Growth (YoY)
96.97%34.67%18.43%-
Cost of Revenue
272.87233.48216.82178.46
Gross Profit
539.17178.7889.3180.02
Selling, General & Admin
392.47491.37441.03294.51
Research & Development
101.58113.92116.88101.27
Total Operating Expenses
494.06605.29557.91395.78
Operating Income
45.11-257.12-319.55-315.76
Interest Income
16.57.1211.260.95
Interest Expense
-56.85-50.03-31.61-26.68
Other Non-Operating Income (Expense)
-72.8518.14-1.5120.66
Total Non-Operating Income (Expense)
-113.2-24.77-21.86-5.07
Pretax Income
-68.09-281.89-341.42-320.83
Net Income
-68.09-378.26-462.53-320.83
Net Income Attributable to Preferred Dividends
-96.37121.11-
Net Income to Common
-68.09-378.26-462.53-320.83
Shares Outstanding (Basic)
16735350
Shares Outstanding (Diluted)
16735350
Shares Change (YoY)
371.04%1.59%104626.23%-
EPS (Basic)
-3.22-10.66-13.24-12.00
EPS (Diluted)
-3.22-10.66-13.24-12.00
Free Cash Flow
66.9-253.64-298.42-327.96
Free Cash Flow Per Share
0.40-7.15-8.54-9829.27
Gross Margin
66.40%43.37%29.17%30.96%
Operating Margin
5.56%-62.37%-104.38%-122.16%
Profit Margin
-8.38%-68.38%-111.53%-124.12%
FCF Margin
8.24%-61.53%-97.48%-126.88%
EBITDA
67.73-208.21-270.55-267.5
EBITDA Margin
8.34%-50.50%-88.38%-103.49%
EBIT
45.11-257.12-319.55-315.76
EBIT Margin
5.56%-62.37%-104.38%-122.16%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q